Tumor immune evasion arises through loss of TNF sensitivity
- PMID: 29776993
- DOI: 10.1126/sciimmunol.aar3451
Tumor immune evasion arises through loss of TNF sensitivity
Abstract
Immunotherapy has revolutionized outcomes for cancer patients, but the mechanisms of resistance remain poorly defined. We used a series of whole-genome clustered regularly interspaced short palindromic repeat (CRISPR)-based screens performed in vitro and in vivo to identify mechanisms of tumor immune evasion from cytotoxic lymphocytes [CD8+ T cells and natural killer (NK) cells]. Deletion of key genes within the tumor necrosis factor (TNF) signaling, interferon-γ (IFN-γ) signaling, and antigen presentation pathways provided protection of tumor cells from CD8+ T cell-mediated killing and blunted antitumor immune responses in vivo. Deletion of a number of genes in the TNF pathway also emerged as the key mechanism of immune evasion from primary NK cells. Our screens also identified that the metabolic protein 2-aminoethanethiol dioxygenase (Ado) modulates sensitivity to TNF-mediated killing by cytotoxic lymphocytes and is required for optimal control of tumors in vivo. Remarkably, we found that tumors delete the same genes when exposed to perforin-deficient CD8+ T cells, demonstrating that the dominant immune evasion strategy used by tumor cells is acquired resistance to T cell-derived cytokine-mediated antitumor effects. We demonstrate that TNF-mediated bystander killing is a potent T cell effector mechanism capable of killing antigen-negative tumor cells. In addition to highlighting the importance of TNF in CD8+ T cell- and NK cell-mediated killing of tumor cells, our study also provides a comprehensive picture of the roles of the TNF, IFN, and antigen presentation pathways in immune-mediated tumor surveillance.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Similar articles
-
Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.Cell Rep. 2019 Sep 10;28(11):2784-2794.e5. doi: 10.1016/j.celrep.2019.08.017. Cell Rep. 2019. PMID: 31509742
-
Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.Cancer Biother Radiopharm. 2010 Feb;25(1):21-8. doi: 10.1089/cbr.2009.0714. Cancer Biother Radiopharm. 2010. PMID: 20187793
-
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors.Blood. 2006 Feb 15;107(4):1342-51. doi: 10.1182/blood-2005-08-3485. Epub 2005 Oct 13. Blood. 2006. PMID: 16223768 Free PMC article.
-
Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).Int J Oncol. 2008 Mar;32(3):527-35. Int J Oncol. 2008. PMID: 18292929 Review.
-
A knockout approach to understanding CD8+ cell effector mechanisms in adaptive immunity to Listeria monocytogenes.Immunobiology. 1999 Dec;201(2):196-204. doi: 10.1016/S0171-2985(99)80059-X. Immunobiology. 1999. PMID: 10631568 Review.
Cited by
-
Cysteamine dioxygenase (ADO) governs cancer cell mitochondrial redox homeostasis through proline metabolism.Sci Adv. 2024 Oct 4;10(40):eadq0355. doi: 10.1126/sciadv.adq0355. Epub 2024 Oct 2. Sci Adv. 2024. PMID: 39356760 Free PMC article.
-
Transcriptome Analysis Reveals Possible Immunomodulatory Activity Mechanism of Chlorella sp. Exopolysaccharides on RAW264.7 Macrophages.Mar Drugs. 2021 Apr 14;19(4):217. doi: 10.3390/md19040217. Mar Drugs. 2021. PMID: 33919822 Free PMC article.
-
Hypothesis: Mutations and Immunosurveillance in Obesity-Associated Colorectal Cancer.J Cancer. 2022 Aug 8;13(10):3044-3050. doi: 10.7150/jca.76052. eCollection 2022. J Cancer. 2022. PMID: 36046651 Free PMC article.
-
Targeting the epigenetic regulation of antitumour immunity.Nat Rev Drug Discov. 2020 Nov;19(11):776-800. doi: 10.1038/s41573-020-0077-5. Epub 2020 Sep 14. Nat Rev Drug Discov. 2020. PMID: 32929243 Review.
-
Elevated α-1,2-mannosidase MAN1C1 in glioma stem cells and its implications for immunological changes and prognosis in glioma patients.Sci Rep. 2024 Sep 27;14(1):22159. doi: 10.1038/s41598-024-72901-2. Sci Rep. 2024. PMID: 39333557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials